Sugi Predict

Sugi Predict / Compounds / SCHEMBL10102567

SCHEMBL10102567

SCHEMBL10102567

Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 19/20 0.83
▸ ERBB2 P04626 4/20 0.83
▸ KIT P10721 3/20 0.83
▸ SRC P12931 3/20 0.83
▸ ERBB3 P21860 3/20 0.83
▸ ERBB4 Q15303 3/20 0.83
▸ BRAF P15056 2/20 0.83
▸ CIT O14578 2/20 0.83
▸ GAK O14976 2/20 0.83
▸ EPHB6 O15197 2/20 0.83
▸ RIPK2 O43353 2/20 0.83
▸ STK17B O94768 2/20 0.83
▸ STK10 O94804 2/20 0.83
▸ ABL1 P00519 2/20 0.83
▸ LCK P06239 2/20 0.83
▸ LYN P07948 2/20 0.83
▸ RET P07949 2/20 0.83
▸ MET P08581 2/20 0.83
▸ HCK P08631 2/20 0.83
▸ FGR P09769 2/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29577833 0.93 EGFR (0.92) EGFRERBB2KITSRCERBB3
SCHEMBL28713534 0.93 EGFR (0.92) EGFRERBB2KITSRCERBB3
SCHEMBL17921472 0.92 EGFR (0.71) EGFRERBB2KITSRCERBB3
Gefitinib SCHEMBL2770155 0.92 EGFR (0.98) EGFRERBB2KITSRCERBB3
Gefitinib SCHEMBL28098790 0.92 EGFR (0.98) EGFRERBB2KITSRCERBB3
Gefitinib SCHEMBL29351046 0.91 EGFR (1.00) EGFRERBB2KITSRCERBB3
SCHEMBL1734701 0.91 EGFR (1.00) EGFRERBB2KITSRCERBB3
Gefitinib SCHEMBL29351336 0.91 EGFR (1.00) EGFRERBB2KITSRCERBB3
Gefitinib SCHEMBL465143 0.91 EGFR (1.00) EGFRERBB2KITSRCERBB3
Gefitinib SCHEMBL7866 0.91 EGFR (1.00) EGFRERBB2KITSRCERBB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022258684-A1 MIXED SOLVENTS FOR SPRAY DRYING FOR PREPARATION OF AMORPHOUS SOLID DISPERSIONS BEND RESEARCH, INC. (US) 2022-12-15 — — WO disclosed
US-10849982-B2 C3-carbon linked glutarimide degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-12-01 — — US disclosed
US-10660968-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-05-26 — — US disclosed
US-10646575-B2 Heterocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-05-12 — — US disclosed
WO-2019173224-A1 DEUTERATED COMPOUNDS AND CHIMERAS AND USES THEREOF BIOTHERYX, INC. (US) 2019-09-12 — — WO disclosed
US-9617227-B2 Process of preparing a quinazoline derivative SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD. (CN) 2017-04-11 — — US disclosed
US-20170027952-A1 ASSOCIATION BETWEEN 3-[(3--2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND AN EGFR TYR KINASE INHIBITOR LES LABORATOIRES SERVIER (FR) 2017-02-02 — — US disclosed
US-20160200688-A1 Process of Preparing a Quinazoline Derivative SCIANDA (CHANGSHU) PHARMACEUTICALS, LTD. (CN) 2016-07-14 — — US disclosed
US-20160096810-A1 ENANTIOSELECTIVE SYNTHESIS OF DIALKYLATED N,O-HETEROCYCLES BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION CALIFORNIA INSTITUTE OF TECHNOLOGY 2016-04-07 — — US disclosed
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2016-01-07 — — US disclosed
US-9073916-B2 Prodrug forms of kinase inhibitors and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2015-07-07 — — US disclosed
CN-1829793-B Mark gene having differential expression between respondent and non-respondent of erbB receptor tyrosine kinase inhibitor ASTRAZENECA UK LTD 2012-05-09 — — CN disclosed
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2012-03-29 — — US disclosed
CN-1829793-A Process ASTRAZENECA UK LTD (GB) 2006-09-06 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10849982-B2 C3-carbon linked glutarimide degronimers for target protein degradation STUB1, UBE3C, UBE3A EGFR 553/4885ERBB2 501/4885KIT 4485/4885
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY NTRK3, TK1, TNNI3K EGFR 48/4885ERBB2 7/4885KIT 615/4885
US-20160200688-A1 Process of Preparing a Quinazoline Derivative ABL1, EGFR, KRAS EGFR 2/4885ERBB2 4/4885KIT 118/4885
US-20170027952-A1 ASSOCIATION BETWEEN 3-[(3--2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND AN EGFR TYR KINASE INHIBITOR EGFR, ERBB2, ERBB4 EGFR 1/4885ERBB2 2/4885KIT 1675/4885
US-10646575-B2 Heterocyclic degronimers for target protein degradation CRBN, MDM2, STUB1 EGFR 278/4885ERBB2 269/4885KIT 2818/4885
US-10660968-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A EGFR 793/4885ERBB2 711/4885KIT 4712/4885
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY NTRK3, TK1, TNNI3K EGFR 41/4885ERBB2 7/4885KIT 638/4885
US-20160096810-A1 ENANTIOSELECTIVE SYNTHESIS OF DIALKYLATED N,O-HETEROCYCLES BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION ODC1, OSTC, AOC1 EGFR 1178/4885ERBB2 701/4885KIT 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.